Emodin Reduces the Activity of (1,3)-β-D-glucan Synthase from Candida albicans and Does Not Interact with Caspofungin by JANECZKO, MONIKA
ORIGINAL PAPERPolish Journal of Microbiology
2018, Vol. 67, No 4, 463–470
https://doi.org/10.21307/pjm-2018-054
* Corresponding author: M. Janeczko, Department of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland; 
e-mail: mjanec@kul.pl
© 2018 Monika Janeczko
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (https://creativecommons.
org/licenses/by-nc-nd/4.0/)
Introduction
Candidiasis is one of the most prevalent super-
ficial and deep-seated fungal infections in humans 
and, as such, a major global health problem, which is 
additionally associated with a high mortality rate. The 
most pervasive and problematic cause of infections of 
all Candida species is Candida albicans – a part of the 
commensal microbiota of more than half of the healthy 
population. It is a cause of both opportunistic and 
invasive fungal infections (Pfaller and Diekema 2007; 
Sardi et al. 2013). Yeast infections frequently develop 
in immunocompromised patients with AIDS, cancer, 
and neutropenia as well as those receiving immune-
suppressive and antibiotic therapy (Canela et al. 2018). 
Recent reports indicate that Candida infections are 
often associated with bipolar disorder and schizophre-
nia (Severance et al. 2016). The pathogenicity of Can-
dida species is supported by a wide range of virulence 
factors and fitness attributes, such as biofilm formation, 
polymorphism, thigmotropism, phenotypic switching, 
secretion of hydrolytic enzymes, quick adaptation to 
fluctuations in environmental pH, metabolic flexibility, 
and strong stress response mechanisms (Mayer et al. 
2013; Martins et al. 2014).
Due to the similarity of human and fungal cells, dis-
covery of selective antifungal drugs is extremely diffi-
cult. Nevertheless, there are some elements differentiat-
ing both types of cells. One of them is the cell wall that 
does not exist in mammalian cells. (1,3)-β-D-glucan 
is the main polysaccharide in the fungal cell wall. It 
is synthesized in the fungal cell by glucan synthase 
located in the cell membrane. This enzyme is regarded 
as a molecular target in the search for compounds with 
potential antifungal activity. Echinocandins, the current 
antifungal drugs are the inhibitors of (1,3)-β-D-glucan 
synthase (Denning 2003).
Echinocandins represented by anidulafungin, 
caspofungin, and micafungin target the synthesis of 
(1,3)-β-D-glucan polymers through non-competitive 
Emodin Reduces the Activity of (1,3)-β-D-glucan Synthase
from Candida albicans and Does Not Interact with Caspofungin
MONIKA JANECZKO*
Department of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland
Submitted 20 June 2018, revised 7 July 2018, accepted 4 September 2018
A b s t r a c t
Candidiasis is the most common opportunistic yeast infection, with Candida albicans as a paramount causative species. (1,3)-β-D-glucan is 
one of the three main targets of clinically available antifungal agents used to treat Candida infections. It is one of the most abundant fungal 
cell wall components. Echinocandins represent the newest class of antifungals affecting cell wall biosynthesis through non-competitive 
inhibition of (1,3)-β-D-glucan synthase. Therefore, treatment with echinocandins causes defects in fungal cell integrity. In the present 
study, similar activity of emodin (6-methyl-1,3,8-trihydroxyanthraquinone) has been revealed. Many reports have already shown the anti-
fungal potential of this pleiotropic molecule, including its activity against C. albicans. The aim of this report was to evaluate the activity of 
emodin towards a new molecular target, i.e. (1,3)-β-D-glucan synthase isolated from Candida cells. Moreover, given the identical mecha-
nism of the activity of both molecules, interaction of emodin with caspofungin was determined. The study revealed that emodin reduced 
(1,3)-β-D-glucan synthase activity and increased cell wall damage, which was evidenced by both a sorbitol protection assay and an aniline 
blue staining assay. Furthermore, the synergy testing method showed mainly independence of the action of both tested antifungal agents, 
i.e. emodin and caspofungin used in combination.
K e y  w o r d s: Candida albicans, caspofungin, echinocandins, emodin, (1,3)-β-D-glucan synthase
Janeczko M. 4464
inhibition of the glucan synthase enzyme. Inhibition 
of a  fungal-specific target by these antibiotics leads 
to defects in fungal cell wall integrity (Pianalto and 
Alspaugh 2016).
Despite the effectiveness of echinocandins in the 
control of many fungal infections, antifungal resistance 
and defensive mechanisms resulting from the use of 
these drugs have been observed in fungal cells. One of 
the beneficial alternatives for potentiating the antifungal 
drugs is combination therapy comprising an antibiotic 
with a natural product (Zacchino et al. 2017). A combi-
nation of several medicinal substances can significantly 
improve the therapeutic properties and reduce the effec-
tive concentration of antibiotics while eliminating their 
side effects (Martins et al. 2014; Singh and Yeh 2017).
In the light of these facts, the medicinal potential 
of phytochemicals, their synergistic action with anti-
fungal agents, and their interrelated mechanisms of 
action have been extensively studied (Kanafani and 
Perfect 2008; Sher 2009; Agarwal et al. 2010). Emodin 
(6-methyl-1,3,8-trihydroxyanthraquinone) is one of 
the most promising natural compounds. Many reports 
regard emodin as a plant component with antioxidant, 
antibacterial, antiviral, antimutagenic, antitumor, and 
immunosuppressive properties (Shrimali et al. 2013; 
Dong et al. 2016). The latest research on the biological 
activity of this compound points to its anti-C. albicans 
activity (Kong et al. 2009; Janeczko et al. 2017).
The aim of the present study was to evaluate the 
inhibitory properties of emodin against (1,3)-β-D-
glucan synthase from C. albicans cells. Moreover, the 
influence of the compound on C. albicans cell wall 
destruction was evidenced with the use of a sorbitol 
protection assay and aniline blue staining. A checker-
board microliter plate assay was also used to determine 
the FICI (Fractional Inhibitory Concentration Index) in 
order to evaluate the combined activities of emodin and 
caspofungin against C. albicans strains by determining 
the FICI (Fractional Inhibitory Concentration Index).
Experimental
Materials and Methods
C. albicans strains. The experiments were per-
formed on C. albicans reference strain ATCC 10231. 
Additionally, 20 clinical strains isolated from urinary 
tracts and 20 clinical strains isolated from reproduc-
tive systems of gynecological patients of Jan Boży Inde-
pendent Public Provincial Hospital in Lublin, Poland, 
were included in this study. The strains were identified 
using VITEK 2 YST IC CARDS (Biomerieux).
Determination of Minimal Inhibitory Concentra-
tions (MICs). The MICs of emodin (Sigma-Aldrich, 
USA), caspofungin (Sigma-Aldrich, USA), and ampho-
tericin B (Sigma-Aldrich, USA) were determined with 
the broth dilution method as recommended by CLSI, 
with some modifications (CLSI 2017). Two-fold serial 
dilutions of emodin (0.8–400 µg/ml) or antibiotics 
(0.015–10 µg/ml) were prepared in 96-well microtiter 
plates using RPMI-1640 medium (with L-glutamine 
and phenol red, without bicarbonate) (Sigma-Aldrich, 
USA) buffered with 0.165 M 3-(N-morpholino)propane 
sulfonic acid (MOPS) (Sigma-Aldrich, USA). Adjacent 
wells of the microtiter plates contained 100 μl of each 
dilution. The inoculum was prepared by dilution of 
C. albicans cells with RPMI. The turbidity of this sus-
pension was adjusted to 1–5 × 103 at a 530 nm wave-
length. After addition of 20 μl of the inoculum to the 
wells, the plates were incubated at 37°C for 48 hours. 
100 μl of uninoculated medium was included as a ste-
rility control (blank). The MIC was taken as the low-
est concentration of disinfectant that inhibits fungal 
growth. The experiments were performed in triplicate.
Sorbitol protection assay. The sorbitol protection 
assay was carried out to determine the effect of emodin 
on the destabilization of the fungal cell membrane. To 
this end, duplicate plates containing either emodin or 
amphotericin B and caspofungin were prepared as con-
trols. One plate from each pair contained only the sub-
stance tested and the other plate contained an adequate 
antifungal and, additionally, 0.8 M sorbitol as an osmotic 
protectant (Frost et al. 1995). MICs for each trial were 
determined by the modified CLSI protocol as described 
above. Each assay was performed in triplicate.
Preparation and quantification of (1,3)-β-D-
glucan synthase. (1,3)-β-D-glucan synthase from 
C. albi cans cells (ATCC 10231) was prepared using the 
method proposed by Shedletzky et al. (1997) with some 
modifications described by Lee and Kim (2016). The 
enzyme was isolated from C. albicans cells cultivated 
in 1 l of Sabouraud Dextrose Agar Broth (Biocorp, 
Poland) at 37°C for 16 h. The cells were homogenized 
in a Bead Beater (Minilys Homogenizer, Bertin Instru-
ments) in 12 cycles of 1 min with 0.5-mm acid-washed 
glass beads. The protein concentration in the micro-
some and membrane fraction was measured using the 
Bradford method in accordance with the manufactur-
er’s instructions (Sigma-Aldrich, USA). The (1,3)-β-D-
glucan synthase assay was performed according to the 
method developed by Frost et al. (1995) and modified 
by Lee and Kim (2016). The glucans stained specifically 
with aniline blue solution (0.1%) were a measure of 
the enzyme activity. Fluorescence was measured using 
a spectrofluorometer (Pharmacia Biotech) at 400-nm 
excitation and 460-nm emission wavelengths. The effect 
of emodin on the enzyme activity was determined at 
concentrations corresponding to the MIC/4, MIC/2, 
MIC, and 2 × MIC, and DMSO was used as a control. 
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The assays were performed in triplicate in three inde-
pendent experiments.
Aniline blue staining of (1,3)-β-glucan in the 
C. albicans cell wall. The aniline blue staining method 
and fluorescence microscopy were used to visualize the 
effect of emodin and caspofungin on (1,3)-β-D-glucans 
in the C. albicans (ATCC 10231) cell walls. The yeast 
cells at the exponential phase were harvested by cen-
trifugation at 4500 × g at 4°C for 5 min. Next, the cells 
were washed twice and resuspended in 0.85% NaCl. 
Emodin at concentrations corresponding to MIC/2 
and MIC/4, caspofungin at MIC/2, and 1% DMSO as 
control were added to the cell suspensions and incu-
bated at 37°C for 10 h. The cells were harvested and 
washed in 0.85% NaCl; next, the cell density of each 
experimental group was adjusted to 1 × 108 cells/ml and 
the cells were resuspended in an aniline blue solution 
(0.1%). The samples were stained at 50°C for 30 min. 
A drop of each suspension was squashed between the 
microscope slide and the cover glass. The preparation 
was sealed and examined in a fluorescence microscope 
under UV illumination (Nicon). Images were taken 
with a cooled monochrome camera.
Caspofungin – emodin combination assay (a che-
cker board method). Interactions between caspofungin 
and emodin were measured by calculation of the frac-
tional inhibitory concentration index (FICI). A total of 
l00 μl of RPMI-1640 medium was distributed into each 
well of the microdilution plates. The first antibiotic of the 
combination – caspofungin was serially diluted along 
the ordinate at a concentration range of 0–1.2 µg/ml, 
while the other drug – emodin was diluted along the 
abscissa at a concentration range of 0–100 µg/ml. The 
inoculum was prepared from C. albicans in RPMI-1640 
medium as described in the MIC assay. Each microtiter 
well was inoculated with 20 µl of the yeast inoculum 
and the plates were incubated at 37°C for 48 h. The 
MIC values were detected with the naked eye. The FICI 
values were calculated for each well with the equation 
FICI = FICA + FICB = (MICA+B/MICA) + (MICB + 
+ A/MICB), where MICA and MICB are the MICs of 
drugs A and B alone, respectively, and MICA + B and 
MICB + A are the concentrations of the drugs applied in 
combination, respectively, in all the wells correspond-
ing to the MIC. A combination of two drugs is consid-
ered synergistic when the FICI is ≤ 0.5, indifferent when 
the FICI is > 0.5 to ≤ 4, and antagonistic when the FICI 
is > 4 (Odss 2003; Petersen et al. 2006).
Results and Discussion
Emodin is a natural anthraquinone derivative found 
mainly in the roots and rhizomes of numerous plants. 
Pharmacological studies have demonstrated that emo-
din with its various biological functions has been used 
in the treatment of cancers and inflammatory diseases 
(Wei et al. 2013; Dong et al. 2016; Monisha et al. 2016). 
The unique therapeutic potential of emodin results 
from its ability to interact with many molecular tar-
gets, e.g. protein kinases, NADH-oxidase, topoisomer-
ase II, survivin, XIAP, STAT3, p53, and p21 (Shrimali 
et al. 2013). Furthermore, emodin was found to have 
antimicrobial activity (Alves et al. 2004; Kong et al. 
2009; Liu et al. 2013; Cao et al. 2015; Liu et al. 2015; 
Janeczko et al. 2017).
In this study, the antifungal activity of emodin 
against the reference and clinical strains of C. albicans 
has been confirmed by the CLSI method in RPMI 
medium. The minimal inhibitory concentration against 
the standard strain was 12.5 µg/ml. The control antibi-
otics, caspofungin and amphotericin B, inhibited yeast 
growth at concentrations of 0.15 µg/ml and 1 µg/ml, 
respectively (Table I). Moreover, emodin suppressed the 
growth of all clinical strains isolated from the urinary 
tracts or the vaginas of the gynecological patients. The 
activity against these species has been shown at values 
of MICs between 6.25 and 50 µg/ml. Also, all isolates 
were susceptible to caspofungin. The MICs ranged from 
0.03 to 0.6 µg/ml. The MIC values of the antifungal 
agents tested individually are summarized in Table II 
and Table III. These results were comparable to MICs 
obtained in our previous work (Janeczko et al. 2017). As 
demonstrated in the previous study, emodin suppressed 
the growth of C. albicans and other reference strains, 
such as C. krusei, C. parapsilosis, and C. tropicalis, as 
well as clinical Candida strains. In addition, fungicidal 
activity against these species has been shown at values 
of MICs and MFCs (Minimal Fungicidal Concentra-
tions) between 12.5 and 200 µg/ml. Moreover, we have 
proved that this compound has anti-virulent potential 
by reducing hyphal formation, suppressing adhesion, 
which is the first and critical phase of fungal infection, 
and destabilizing fully established biofilm. In terms 
of the high pleiotropic nature of emodin, it has been 
confirmed that this compound is an effective inhibitor 
of protein kinase 2 (CK2) isolated from C. albicans cells 
(Janeczko et al. 2017).
In order to verify the influence of emodin on C. albi-
cans cells, the previous research on the molecular 
Emodin 12.5 25
Caspofungin  0.15  0.6
Amphotericin B  1  1
Table I
Effect of sorbitol on the MICs of emodin and antibiotics against
C. albicans ATCC 10231.
MIC (µg/ml)
Without sorbitol With sorbitol
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impact of this substance has been extended to examina-
tion of its effect on cell wall damage. The yeast cell wall 
serves many functions, inter alia providing cell rigidity 
and shape, metabolism, ion exchange, and interactions 
with host defense mechanisms. Since the cell wall is 
not present in mammalian cells, it is an excellent target 
for specific antifungal antibiotics with higher selectiv-
ity towards pathogen cells and lower toxicity against 
host cells (Denning and Hope 2010). The damaging 
effects on the C. albicans cell wall were evaluated on 
the basis of the MICs of emodin, caspofungin (positive 
control), and amphotericin B (negative control) in the 
absence and presence of sorbitol. Reduction of crucial 
cell wall components by antifungal agents will lyse cells 
in the absence of an osmoprotectant. These effects can 
be recovered in the presence of such osmoprotectants 
as sorbitol: in this case, cells will continue to grow. As 
shown in Table I, the MIC of emodin increased twice in 
relation to the sample without any osmoprotectant after 
2 days of incubation. The MIC of caspofungin increased 
three times without any sorbitol after the same incu-
bation time. In contrast, the MIC of amphotericin B 
did not change. The increase in the MIC in the presence 
of sorbitol demonstrated that emodin was involved in 
cell wall synthesis.
The fungal cell wall is a unique structure built of 
α- and β-linked glucans, chitin, polysaccharides, and 
mucopolysaccharides. Many of these biopolymers 
are essential for proper functioning of fungal cells. 
Enzymes synthesizing these biopolymers could be 
desirable antifungal targets (Wiederhold 2018). Since 
emodin is a  highly pleiotropic molecule capable of 
interacting with several major molecular targets and 
damaging C. albicans cell walls, the influence of the 
compound on the activity of (1,3)-β-D-glucan synthase 
(GS) has been analyzed. This enzyme is a glucosyltrans-
ferase involved in synthesis of 1,3-β-D-glucan in fungi 
– one of the main molecular targets used in clinically 
available antifungals and also a pharmacological target 
for echinocandins (Denning 2003). Inhibition of GS 
activity and the following depletion of β-glucans from 
the fungal cell wall result in cell lysis under osmotic 
stress (Frost et al. 1995).
An aniline blue assay was used to determine the 
effect of emodin on the activity of (1,3)-β-D-glucan 
synthase obtained from a microsomal membrane frac-
tion from C. albicans. The decrease in the GS activity 
after the treatment with the anthraquinone tested was 
shown as a percentage of the DMSO control. As shown 
in Fig. 1, emodin reduced the GS activity approxi-
Table II
In vitro activity of emodin and caspofungin alone and in combination assessed by the broth
dilution assay against clinical strains of C. albicans isolated from urinary tracts.
Strain
No.
MIC of the drug used alone
(µg/ml)
MIC of the drug used
in combination (µg/ml) FICI Interaction
Emodin Caspofungin
 1 12.5 0.15 12.5 + 0.3 3 Indifferent
 2 12.5 0.07 12.5 + 0.3 5.28 Antagonism
 3 25 0.3 25 + 0.6 3 Indifferent
 4 25 0.3 25 + 0.3 2 Indifferent
 5 50 0.6 50 + 1.2 3 Indifferent
 6 50 0.15 50 + 0.3 3 Indifferent
 7 12.5 0.15 12.5 + 0.3 3 Indifferent
 8 12.5 0.07 12.5 + 0.3 5.28 Antagonism
 9 25 0.03 25 + 0.15 6 Antagonism
10 25 0.3 25 + 0.15 1.5 Indifferent
11 25 0.15 25 + 0.3 3 Indifferent
12 50 0.6 50 + 0.3 1.5 Indifferent
13 50 0.3 50 + 0.3 2 Indifferent
14 50 0.6 50 + 0.6 2 Indifferent
15 25 0.3 25 + 0.15 1.5 Indifferent
16  6.25 0.03 12.5 + 0.06 4 Indifferent
17 50 0.6 50 + 0.6 2 Indifferent
18 50 0.3 50 + 0.3 2 Indifferent
19 50 0.15 25 + 0.15 1.5 Indifferent
20 25 0.6 50 + 0.6 3 Indifferent
Emodin + Caspofungin
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mately to 67.6% ± 3.4%, 76% ± 4%, 87.4% ± 5,2%, and 
91.2% ± 3,8% at concentrations equal to 2 × MIC, MIC, 
MIC/2, and MIC/4, respectively, when compared to the 
DMSO control cells. The reduced activity of GS proved 
that emodin prevented the synthesis of the C. albicans 
cell wall, and therefore, the effect of its activity corre-
sponds to that of echinocandins.
Additionally, aniline blue was used to verify the in 
vivo influence of emodin on changes in the content of 
(1,3)-β-D-glucans in C. albicans by inhibition of their 
biosynthesis. This fluorescent dye binds to (1,3)-β-D-
glucans in the cell wall. The biosynthesis of C. albicans 
cell wall components was shut down by inhibition of 
GS. The fungi were grown in the presence of emodin 
at the concentrations of 6.25 µg/ml and 3.12 µg/ml 
corresponding to MIC/2 and MIC/4, respectively or 
in the presence of caspofungin at 0.07 µg/ml (MIC/2). 
The control contained DMSO at the same concentra-
tion as in the samples with emodin. As shown in Fig. 2, 
the intensity of fluorescence of fungal cells stained with 
blue aniline was lower in cells treated with emodin and 
caspofungin than in the controls. The apparent signifi-
cant loss of fluorescence of the fungal cell walls and, 
above all, the disintegration of cells under the pressure 
of caspofungin at MIC/2 correlated with the sensitivity 
of this species to echinocandin, i.e. a 1,3-β-D-glucan 
synthesis inhibitor (Fig. 2B). The treatment of C. albi-
cans cells with emodin at concentrations MIC/2 and 
MIC/4 resulted in reduction of the number of cells, but 
the reduction of the glucan content in the cell walls was 
almost imperceptible (Fig. 2C and Fig. 2D).
Recently, natural product screening has also been 
a source of a number of distinct GS inhibitors. Anti-
fungal activity was shown by natural lipopeptides and 
triterpenes containing a polar (acidic) moiety (Vicente 
Table III
In vitro activity of emodin and caspofungin alone and in combination assessed by the broth
dilution method against clinical strains of C. albicans isolated from vaginas.
Strain
No.
MIC of the drug used alone
(µg/ml)
MIC of the drug used
in combination (µg/ml) FICI Interaction
Emodin Caspofungin Emodin + Caspofungin
 1 50 0.3 50 + 0.3 2 Indifferent
 2 50 0.6 50 + 0.6 2 Indifferent
 3 25 0.15 25 + 0.3 3 Indifferent
 4 50 0.3 50 + 0.3 2 Indifferent
 5 25 0.15 25 + 0.3 3 Indifferent
 6 50 0.07 25 + 0.15 2.64 Indifferent
 7 50 0.3 50 + 0.6 3 Indifferent
 8 50 0.6 25 + 0.3 1 Indifferent
 9 12.5 0.3 25 + 0.3 3 Indifferent
10 50 0.15 50 + 0.6 5 Antagonism
11 50 0.07 50 + 0.15 3 Indifferent
12 50 0.6 50 + 0.3 1.5 Indifferent
13 25 0.3 50 + 0.3 3 Indifferent
14 25 0.6 50 + 0.15 2.25 Indifferent
15 25 0.3 50 + 0.15 2.5 Indifferent
16 12.5 0.03 25 + 0.15 5 Antagonism
17 12.5 0.6 12.5 + 0.6 2 Indifferent
18 50 0.3 50 + 0.6 3 Indifferent
19 50 0.15 25 + 0.07 1 Indifferent
20 50 0.6 50 + 0.3 1.5 Indifferent
Fig. 1. Effect of emodin on (1,3)- β-D-glucan synthase activity.
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et al. 2003). In addition, several new investigational 
agents are currently under development. Among these, 
there are semi-synthetic enfumafungins modified by 
replacement with amino ethers (Apgar et al. 2015), 
SCY-078, which derives from enfumafungin, as well 
and a cyclic hexapeptide rezafungin (CD101, biafungin, 
previously SP3025) (Wiederhold 2018).
The clinical success of the echinocandins is asso-
ciated with their fewer toxic side effects in comparison 
to polyenes and their fewer drug-drug interactions 
compared to azoles. These drugs are primarily used 
for the treatment of invasive candidiasis and as an 
alternative therapy for aspergillosis treatment (Odds 
et al. 2003; Denning and Hope 2010). Unfortunately, 
the effectiveness of these antibiotics is compromised 
due to a critical increase in the emergence of drug-
resistant Candida strains. In the face of this problem, 
another strategy has been developed to overcome the 
treatment failures by combining different antifungals. 
Many reviews indicate that the combination of antibio-
tics, phytochemicals, or both natural plant products 
and well-known antibiotics offers significant potential 
for the development of novel antimicrobial therapies 
and treatment of several diseases caused by micro-
organisms. The advantages of the synergistic action 
of antibiotics and plant extracts include reduction of 
Fig. 2. Aniline blue staining of C. albicans cell walls. A) treatment with DMSO at 1% (control); B) caspofungin at 0.07 µg/ml;
C) emodin at 6.25 µg/ml; D) emodin at 3.12 µg/ml.
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undesirable effects and increased efficiency. It is also 
important to increase the stability and bioavailability of 
free agents and achieve an adequate therapeutic effect 
with relatively small doses compared to any synthetic 
medication (Hemaiswarya et al. 2008).
Since emodin affects the activity of (1,3)-β-D-glucan 
synthase in the same range as caspofungin, the inter-
actions between this anthraquinone and the antibiotic 
were investigated. In this case, two possibilities of inter-
action could be expected – synergism or antagonism 
in the action against C. albicans cells. The third option 
was indifferent interaction between the two tested sub-
stances. Synergism is defined as a positive interaction 
occurring when two agents combined together exert 
an inhibitory effect that is greater than the sum of their 
individual effects. In turn, the term antagonism is used 
when the effect of both drugs together is worse than the 
effect of either alone. Then, indifference means that no 
effect is exhibited. The caspofungin-emodin combina-
tion effect was measured using the checkerboard micr-
otiter plate method and calculation of the fractional 
inhibitory concentration index (FICI). The course and 
result of the experiment for the reference C. albicans 
strain is schematically shown in Fig. 3. The combination 
of both antifungals showed a tendency towards indif-
ference between the tested compounds at most concen-
trations and ratios. Thus, emodin at 0.19–3.12 μg/ml 
did not affect the caspofungin activity against C. albi-
cans. Similarly, caspofungin at 0.007–0.6 μg/ml did not 
change the MIC values for emodin. Only in one case, 
the MIC of caspofungin increased from 0.15 μg/ml to 
0.3 μg/ml in the presence of 6.25 μg/ml emodin. Based 
on the MIC values in various concentration combina-
tions of both antifungal compounds, the FICI was 3 and 
did not show any interactions between the compounds.
The checkerboard assays evaluated against 40 clini-
cal isolates of C. albicans showed that the combination 
of emodin with caspofungin changed mainly the MIC 
values with respect to caspofungin. MICs increased for 
18 strains, decreased for nine strains, and remained 
unchanged for 13 isolates. The composite emodin/
caspofungin caused a change in the MICs with respect 
to emodin to a lesser extent. The MIC values decreased 
for four strains and increased for five strains. They were 
ca. 2–4-fold lower or higher than the values for the 
compounds applied alone. The FICI values of the com-
binations of the antifungal drugs ranged from 1 to 6. 
This combination showed predominantly indifferent 
interactions between emodin and caspofungin (87.5% 
isolates) with the FICI in the range from 1 to 4. An 
antagonistic effect was proved only against five strains 
tested (12.5%) with FICI > 4. Otherwise, no synergism 
was observed (FICI < 0.5). These results were compara-
ble to the FICI of the C. albicans reference strain. The 
MIC and FICI values of the antifungal agents tested in 
combination are summarized in Table II and Table III.
In conclusion, as shown above, the antifungal activ-
ity of emodin against C. albicans may be related to the 
inhibition of (1,3)-β-D-glucan synthase activity, lead-
ing to disruption of (1,3)-β-D-glucans in the fungal cell 
wall. This completely new molecular target for emodin 
is highly desirable due to the high specificity of this type 
of antifungals in relation to host cells. The novel mecha-
nism of emodin action could hypothetically amplify 
the activity of echinocandins; however, in combination 
with caspofungin, this anthraquinone shows indifferent 
or antagonistic interactions. The data from the studies 
of the interactions between emodin/caspofungin sug-
gest that these combinations could not be an effective 
strategy against C. albicans infections.
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Fig. 3. The checkerboard method showing unresponsiveness of the emodin-caspofungin combination.
The resulting checkerboard included each combination of emodin and caspofungin, with wells containing
the highest concentration of each compounds in opposite corners (darkened fields mean cell growth;
light fields mean no growth).
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